SymBio Pharmaceuticals Limited
4582.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.02 | -0.49 | -0.15 |
| FCF Yield | -38.29% | -4.34% | 6.24% | 0.17% |
| EV / EBITDA | -1.33 | -4.68 | 9.13 | 36.05 |
| Quality | ||||
| ROIC | -92.26% | -11.25% | 12.92% | 14.65% |
| Gross Margin | 76.37% | 78.91% | 75.94% | 70.28% |
| Cash Conversion Ratio | 0.89 | 0.10 | 0.77 | 0.07 |
| Growth | ||||
| Revenue 3-Year CAGR | -37.42% | -12.18% | 49.64% | 20,208,207.86% |
| Free Cash Flow Growth | -703.85% | -127.29% | 1,955.88% | 101.78% |
| Safety | ||||
| Net Debt / EBITDA | 1.05 | 9.13 | -3.05 | -3.48 |
| Interest Coverage | -194.38 | -70.72 | 42.81 | 539.85 |
| Efficiency | ||||
| Inventory Turnover | 2.43 | 5.08 | 5.13 | 6.36 |
| Cash Conversion Cycle | 213.39 | 131.48 | 140.10 | 142.01 |